Disclaimer: Due to limited proficiency, errors are inevitable, and some information may not be the latest. Corrections are welcome in the comments. This article is only an introduction to medical and health-related drugs, not a recommendation of treatment plans (if involved); it does not constitute any investment advice.
Recently, MaxCyte (NASDAQ: MXCT), a leading company specializing in cell engineering and providing enabling platform technologies for the discovery, development, and commercialization of next-generation cell therapy drugs, announced that it has signed a Strategic Platform License (SPL) agreement with Anocca AB, a leader in T-cell immunotherapy at the clinical stage. Anocca AB will utilize MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support the scaled development and production of its deep TCR-T cell therapy pipeline.According to the SPL, Anocca AB has obtained non-exclusive research, clinical, and commercial usage rights to utilize MaxCyte's Flow Electroporation® technology and ExPERT™ platform; MaxCyte is entitled to receive annual licensing fees and milestone and/or sales-based revenues associated with the project.MaxCyte President and CEO Maher Masoud stated: "We are extremely honored to collaborate with Anocca to advance its TCR-T therapy from clinical trials to application. Leveraging our globally supported and regulatory-approved ExPERT™ platform, along with our deep technical expertise, we will help Anocca accelerate clinical-grade production and cell engineering processes. The ExPERT™ platform offers excellent scalability and flexibility, providing high-performance non-viral gene editing solutions across Anocca’s diverse therapeutic pipeline."Anocca AB's cell therapy manufacturing facility in Sweden has recently received GMP compliance certification and a manufacturing license from Swedish regulatory authorities. Its core project targeting KRAS mutation-driven advanced pancreatic cancer has entered the clinical development stage. By incorporating MaxCyte's ExPERT™ platform, Anocca will gain access to a high-quality, scalable technology platform, further enhancing its capability to deliver gene-edited cell therapies.MaxCyte is committed to "Building Better Cells Together." As a leader in the field of cell engineering, we drive the discovery, development, and commercialization of next-generation cell therapies. Our Flow Electroporation® technology and SeQure DX™ gene editing risk assessment services enable precise, efficient, and scalable cell engineering. Backed by professional scientific, technical, and regulatory support, our platform assists researchers worldwide in engineering various cell types and payloads, accelerating the development of safe and effective therapies. For over 25 years, the company has continuously pushed the boundaries of cell engineering, shaping the future of medicine.Reference: Company Announcement
